Introduction
This was a follow-up paper built on our earlier clinical trial investigating the effect of macular carotenoid supplementation in individuals with Alzheimer’s disease. The primary focus here was to provide a more detailed account of the response to supplementation in terms of visual and cognitive function, and to robustly assess the safety profile of long-term carotenoid intake in this vulnerable population.
Why was the research undertaken?
Following the success of our 2015 clinical trial, which showed encouraging results in visual and memory outcomes in patients with mild to moderate Alzheimer’s disease, there remained key questions about the variability of response between individuals and the long-term safety of the supplement. This study aimed to deepen our understanding of both.
How was the study conducted?
The same patient population from the original Alzheimer’s trial was analysed over a 12-month period. Participants were supplemented with a daily capsule containing 10mg lutein, 10mg meso-zeaxanthin, and 2mg zeaxanthin. Researchers assessed macular pigment optical density, blood carotenoid levels, cognitive performance, and visual outcomes, alongside detailed clinical pathology measures to track any adverse events or biochemical changes over time.
What were the results?
The data confirmed that patients with Alzheimer’s disease respond well to supplementation. Macular pigment and blood carotenoid levels increased significantly, and these increases were associated with improvements in visual function and memory-related tasks. Importantly, the supplement was found to be safe and well tolerated, with no adverse effects reported across any of the standard safety markers. Additionally, caregivers reported positive behavioural and mood changes in many patients.
What is the societal benefit?
This paper provided strong additional support for the use of macular carotenoid supplementation in patients with Alzheimer’s disease. It reinforced the supplement’s safety, its consistency of benefit, and its potential to serve as part of a nutritional co-management strategy. As the global burden of Alzheimer’s continues to grow, having a safe, well-tolerated intervention that supports both vision and cognitive function could significantly enhance quality of life for patients and caregivers alike.
